{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:32:19Z","timestamp":1777429939595,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"am","delay-in-days":272,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JPJ008837"],"award-info":[{"award-number":["JPJ008837"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003993","name":"Ministry of Agriculture, Forestry and Fisheries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.parint.2023.102774","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:53:22Z","timestamp":1687794802000},"page":"102774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vitro screening of compounds from the Food and Drug Administration-approved library identifies anti-Babesia gibsoni activity of idarubicin hydrochloride and vorinostat"],"prefix":"10.1016","volume":"96","author":[{"given":"Hang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloiza May","family":"Galon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuowei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thom","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moaz M.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuenan","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parint.2023.102774_bb0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13071-018-2722-y","article-title":"Molecular evidence for the transovarial passage of Babesia gibsoni in Haemaphysalis hystricis (Acari: Ixodidae) ticks from Taiwan: a novel vector for canine babesiosis","volume":"11","author":"Jongejan","year":"2018","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.parint.2023.102774_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vetpar.2018.03.001","article-title":"Antiprotozoal treatment of canine babesiosis","volume":"254","author":"Baneth","year":"2018","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.parint.2023.102774_bb0015","series-title":"Canine Parasites and Parasitic Diseases","year":"2019"},{"key":"10.1016\/j.parint.2023.102774_bb0020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13071-016-1596-0","article-title":"A review of canine babesiosis: the European perspective","volume":"9","author":"Solano-Gallego","year":"2016","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.parint.2023.102774_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2460\/javma.235.5.535","article-title":"Detection of Babesia gibsoni and the canine small Babesia \u2018Spanish isolate\u2019 in blood samples obtained from dogs confiscated from dogfighting operations","volume":"235","author":"Yeagley","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.parint.2023.102774_bb0030","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/ani12060730","article-title":"Babesia gibsoni infection in dogs-a European perspective","volume":"12","author":"Teodorowski","year":"2022","journal-title":"Animals"},{"key":"10.1016\/j.parint.2023.102774_bb0035","first-page":"119","article-title":"Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment","volume":"6","author":"Kelly","year":"2015","journal-title":"Vet. Med. Res. Rep."},{"key":"10.1016\/j.parint.2023.102774_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107831","article-title":"Drug screening of food and drug administration-approved compounds against Babesia bovis in vitro","volume":"210","author":"Li","year":"2020","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.parint.2023.102774_bb0045","article-title":"Computational chemogenomics drug repositioning strategy enables the discovery of epirubicin as a new repurposed hit for Plasmodium falciparum and P. vivax","volume":"64","author":"Ferreira","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2023.102774_bb0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1292\/jvms.64.571","article-title":"Continuous in vitro culture of erythrocytic stages of Babesia gibsoni and virulence of the cultivated parasite","volume":"64","author":"Sunaga","year":"2002","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.parint.2023.102774_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2020.102054","article-title":"Closing the empty anti-Babesia gibsoni drug pipeline in vitro using fluorescence-based high throughput screening assay","volume":"75","author":"Rizk","year":"2020","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.parint.2023.102774_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2021.102437","article-title":"In vitro screening of novel anti-Babesia gibsoni drugs from natural products","volume":"85","author":"Ji","year":"2021","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.parint.2023.102774_bb0065","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.01614-15","article-title":"Clofazimine inhibits the growth of Babesia and Theileria parasites in vitro and in vivo","volume":"60","author":"Tuvshintulga","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2023.102774_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/985015","article-title":"A study of naturally acquired canine babesiosis caused by single and mixed Babesia species in Zambia: clinicopathological findings and case management","author":"Nalubamba","year":"2015","journal-title":"J. Parasitol. Res."},{"key":"10.1016\/j.parint.2023.102774_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/138161207780162827","article-title":"Dihydrofolate reductase as a target for chemotherapy in parasites","volume":"13","author":"Gangjee","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.parint.2023.102774_bb0080","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1128\/AAC.00384-08","article-title":"Cloning, expression, and characterization of Babesia gibsoni dihydrofolate reductase-thymidylate synthase: inhibitory effect of antifolates on its catalytic activity and parasite proliferation","volume":"52","author":"Aboge","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2023.102774_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exppara.2007.03.016","article-title":"Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy","volume":"117","author":"Jefferies","year":"2007","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.parint.2023.102774_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1939-1676.2009.0300.x","article-title":"Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin","volume":"23","author":"Sakuma","year":"2009","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.parint.2023.102774_bb0095","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J. Antibiot."},{"key":"10.1016\/j.parint.2023.102774_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2478\/acve-2018-0011","article-title":"Canine babesiosis: where do we stand?","volume":"68","author":"Petra","year":"2018","journal-title":"Acta Vet."},{"key":"10.1016\/j.parint.2023.102774_bb0105","series-title":"Babesiosis of Domestic Animals and Man","first-page":"227","article-title":"Chemotherapy of Babesiosis*","author":"Kuttler","year":"2018"},{"key":"10.1016\/j.parint.2023.102774_bb0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.parint.2023.102774_bb0115","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1148\/radiol.2019182399","article-title":"Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial","volume":"291","author":"Guiu","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.parint.2023.102774_bb0120","series-title":"LiverTox: clinical and research information on drug-induced liver injury","author":"Doxorubicin","year":"2012"},{"key":"10.1016\/j.parint.2023.102774_bb0125","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/21505594.2020.1770493","article-title":"Insights into idarubicin antimicrobial activity against methicillin-resistant Staphylococcus aureus","volume":"11","author":"She","year":"2020","journal-title":"Virulence"},{"key":"10.1016\/j.parint.2023.102774_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115158","article-title":"DNA topoisomerases in the unicellular protozoan parasites: unwinding the mystery","volume":"203","author":"Lamba","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.parint.2023.102774_bb0135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.parint.2023.102774_bb0140","first-page":"7521","article-title":"Vorinostat as potential antiparasitic drug","volume":"24","author":"Herrera-Mart\u00ednez","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.parint.2023.102774_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpddr.2016.12.005","article-title":"Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth","volume":"7","author":"Chua","year":"2017","journal-title":"Int. J. Parasitol-Drug"},{"key":"10.1016\/j.parint.2023.102774_bb0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/CS20120504","article-title":"Histone deacetylases as targets for treatment of multiple diseases","volume":"124","author":"Tang","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.parint.2023.102774_bb0155","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357692300051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357692300051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:37:10Z","timestamp":1761302230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138357692300051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":31,"alternative-id":["S138357692300051X"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2023.102774","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro screening of compounds from the Food and Drug Administration-approved library identifies anti-Babesia gibsoni activity of idarubicin hydrochloride and vorinostat","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2023.102774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102774"}}